MAPT and Alzheimer disease: Similar to CSF Aβ42, although CSF t-tau and p-tau are already included in the diagnostic criteria for symptomatic or prodromal AD, they are difficult to use in healthy people at the preclinical stage because of the limitation of obtaining CSF samples.